Abbott (NYSE: ABT) reported Q2 EPS of $0.52, $0.02 better than the analyst estimate of $0.50. Revenue for the quarter came in at $5.2 billion versus the consensus estimate of $5.15 billion.

"We've achieved another quarter of strong sales growth led by our global diagnostics and branded generics businesses," said Miles D. White, chairman and chief executive officer, Abbott. "We're well on track to achieve our financial objectives for the year despite a challenging currency environment."

• Second-quarter gross margin ratio was ahead of expectations, primarily driven by continued improvements in Diagnostics and Nutrition.
• In the second quarter, Abbott received European approval for Absorb GT1TM, which combines the world's first fully dissolving stent with a next-generation delivery catheter; completed submissions for regulatory approval of Absorb in Japan and the U.S.; submitted for U.S. regulatory approval of its FreeStyle® Libre Pro Flash Glucose Monitoring System for professional use; and received U.S. FDA clearance for a first-of-its-kind blood test for its i-STAT® handheld system to aid in detecting early pregnancy in emergency situations.

Abbott reaffirmed FY15 EPS expectations.

For earnings history and earnings-related data on Abbott (ABT) click here.